Drug Trial Radar · NCT04242498
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
509
Actual
Start
Mar 2, 2020
Primary completion
Nov 9, 2021
Study completion Sep 28, 2022
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Jan 27, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
Conditions
- Hidradenitis Suppurativa
Interventions
BimekizumabDrug
Subjects will receive bimekizumab at pre-specified time-points.
PlaceboOther
Subjects will receive placebo at pre-specified time-points during the Initial Treatment Period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16Time frame: Week 16
Locations
91 sites in 14 countries. Site status is shown where the registry gives one.
Hs0004 50162
Fountain Valley, California
Hs0004 50196
Thousand Oaks, California
Hs0004 50199
Miami, Florida
Hs0004 50152
Orange Park, Florida
Hs0004 50144
Orlando, Florida
Hs0004 50184
Pembroke Pines, Florida
Hs0004 50193
Sandy Springs, Georgia
Hs0004 50223
Savannah, Georgia
Hs0004 50164
Skokie, Illinois
Hs0004 50234
Plainfield, Indiana
Hs0004 50178
Clarkston, Michigan
Hs0004 50105
St Louis, Missouri
Hs0004 50197
Henderson, Nevada
Hs0004 50159
Portsmouth, New Hampshire
Hs0004 50200
Verona, New Jersey
Hs0004 50237
Albuquerque, New Mexico
Hs0004 50211
Durham, North Carolina
Hs0004 50179
Winston-Salem, North Carolina
Hs0004 50145
Columbus, Ohio
Hs0004 50202
Fairborn, Ohio
Hs0004 50150
Philadelphia, Pennsylvania
Hs0004 50236
Greenville, South Carolina
Hs0004 50084
Johns Island, South Carolina
Hs0004 50148
Pflugerville, Texas
Hs0004 30018
Parkville, Australia
Hs0004 30014
St Leonards, Australia
Hs0004 30009
Westmead, Australia
Hs0004 40313
Pleven, Bulgaria
Hs0004 40284
Sofia, Bulgaria
Hs0004 40311
Sofia, Bulgaria
Hs0004 40314
Sofia, Bulgaria
Hs0004 40315
Sofia, Bulgaria
Hs0004 40353
Stara Zagora, Bulgaria
Hs0004 50172
Cobourg, Canada
Hs0004 50135
Edmonton, Canada
Hs0004 50174
London, Canada
Hs0004 50189
St. John's, Canada
Hs0004 50134
Waterloo, Canada
Hs0004 50136
Winnipeg, Canada
Hs0004 40063
Prague, Czechia
Showing 40 of 91 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.